Page 1 | Search Results | Hematology, ASH Education Program

1-20 of 84

Sort by

Sort Order Select

Journal Articles

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Scott F. Huntington

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 252–259.

https://doi.org/10.1182/hematology.2019000030

Published: 2019

Journal Articles

Indolent lymphomas: pushing the pace with novel agents

Caron A. Jacobson

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 279–286.

https://doi.org/10.1182/hematology.2019000032

Published: 2019

Journal Articles

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

Barbara Eichhorst, Moritz Fürstenau, Michael Hallek

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 482–489.

https://doi.org/10.1182/hematology.2019000070

Published: 2019

Journal Articles

MRD evaluation of AML in clinical practice: are we there yet?

Sylvie D. Freeman, Christopher S. Hourigan

Hematology Am Soc Hematol Educ Program (2019) 2019 (1): 557–569.

https://doi.org/10.1182/hematology.2019000060

Published: 2019

Journal Articles

Are CAR T cells better than antibody or HCT therapy in B-ALL?

Michael A. Pulsipher

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 16–24.

https://doi.org/10.1182/asheducation-2018.1.16

Published: 2018

Journal Articles

Sequencing of therapies in relapsed follicular lymphoma

Loretta J. Nastoupil, Christopher R. Flowers, John P. Leonard

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 189–193.

https://doi.org/10.1182/asheducation-2018.1.189

Published: 2018

Journal Articles

Where to start? Upfront therapy for follicular lymphoma in 2018

John P. Leonard, Loretta J. Nastoupil, Christopher R. Flowers

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 185–188.

https://doi.org/10.1182/asheducation-2018.1.185

Published: 2018

Journal Articles

Novel immunotherapy approaches to follicular lymphoma

Christopher R. Flowers, John P. Leonard, Loretta J. Nastoupil

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 194–199.

https://doi.org/10.1182/asheducation-2018.1.194

Published: 2018

Journal Articles

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Naranie Shanmuganathan, Timothy P. Hughes

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 168–176.

https://doi.org/10.1182/asheducation-2018.1.168

Published: 2018

Journal Articles

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura

Kathryn Dane, Shruti Chaturvedi

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 539–547.

https://doi.org/10.1182/asheducation-2018.1.539

Published: 2018

Journal Articles

Relapsed CLL: sequencing, combinations, and novel agents

Jennifer R. Brown

Hematology Am Soc Hematol Educ Program (2018) 2018 (1): 248–255.

https://doi.org/10.1182/asheducation-2018.1.248

Published: 2018

Journal Articles

Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Cindy E. Neunert

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 400–405.

https://doi.org/10.1182/asheducation-2017.1.400

Published: 2017

Journal Articles

Is molecular remission the goal of multiple myeloma therapy?

Faith E. Davies

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 205–211.

https://doi.org/10.1182/asheducation-2017.1.205

Published: 2017

Journal Articles

Novel approaches to therapy in CML

Ravi Bhatia

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 115–120.

https://doi.org/10.1182/asheducation-2017.1.115

Published: 2017

Journal Articles

Follicular lymphoma: are we ready for a risk-adapted approach?

Brad S. Kahl

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 358–364.

https://doi.org/10.1182/asheducation-2017.1.358

Published: 2017

Journal Articles

Treatment-free remission in CML: who, how, and why?

Francois-Xavier Mahon

Hematology Am Soc Hematol Educ Program (2017) 2017 (1): 102–109.

https://doi.org/10.1182/asheducation.V2017.1.102.00014

Published: 2017

Journal Articles

Treatment of older patients with acute lymphoblastic leukemia

Nicola Gökbuget

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 573–579.

https://doi.org/10.1182/asheducation-2016.1.573

Published: 2016

Journal Articles

Second-line therapies in immune thrombocytopenia

Rachael F. Grace, Cindy Neunert

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 698–706.

https://doi.org/10.1182/asheducation-2016.1.698

Published: 2016

Journal Articles

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Eva Hoster, Christiane Pott

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 437–445.

https://doi.org/10.1182/asheducation-2016.1.437

Published: 2016

Journal Articles

Molecular monitoring in chronic myeloid leukemia—how low can you go?

Susan Branford

Hematology Am Soc Hematol Educ Program (2016) 2016 (1): 156–163.

https://doi.org/10.1182/asheducation-2016.1.156

Published: 2016

NARROW

Cure at what (systemic) financial cost? Integrating novel therapies into first-line Hodgkin lymphoma treatment

Indolent lymphomas: pushing the pace with novel agents

Relapsed disease and aspects of undetectable MRD and treatment discontinuation

MRD evaluation of AML in clinical practice: are we there yet?

Are CAR T cells better than antibody or HCT therapy in B-ALL?

Sequencing of therapies in relapsed follicular lymphoma

Where to start? Upfront therapy for follicular lymphoma in 2018

Novel immunotherapy approaches to follicular lymphoma

Molecular monitoring in CML: how deep? How often? How should it influence therapy?

Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura

Relapsed CLL: sequencing, combinations, and novel agents

Management of newly diagnosed immune thrombocytopenia: can we change outcomes?

Is molecular remission the goal of multiple myeloma therapy?

Novel approaches to therapy in CML

Follicular lymphoma: are we ready for a risk-adapted approach?

Treatment-free remission in CML: who, how, and why?

Treatment of older patients with acute lymphoblastic leukemia

Second-line therapies in immune thrombocytopenia

Minimal residual disease in mantle cell lymphoma: insights into biology and impact on treatment

Molecular monitoring in chronic myeloid leukemia—how low can you go?

ASH Publications

American Society of Hematology

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only